Monitoring total hemoglobin concentration changes across neoadjuvant chemotherapy in PgR-positive and PgR-negative breast cancer with diffuse optical tomography

Mirella L. Altoe, Alessandro Marone, Hyun K. Kim, Mariella Tejada, Hanina Hibshoosh, Katherine Crew, Kevin Kalinsky, Dawn L. Hershman, Andreas H. Hielscher

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The aim of this study was to investigate the optical chemotherapy changes induced by neoadjuvant chemotherapy (NAC) in PgR-positive and PgR-negative breast cancer subtypes using a diffuse optical tomographic breast imaging system (DOTBIS). ctTHb reduction in the tumor volume was greater for patients with PgR-negative, a statistically significant difference of 48.91μM, p =.022, which suggest that PgR-negative tumors are generally less resistant to NAC. These observations indicate that PgR negativity may be combined to optically derived biomarkers for predicting pCR during neoadjuvant chemotherapy.

Original languageEnglish (US)
Title of host publicationOptical Tomography and Spectroscopy of Tissue XIII
EditorsSergio Fantini, Paola Taroni
PublisherSPIE
ISBN (Electronic)9781510623903
DOIs
StatePublished - 2019
EventOptical Tomography and Spectroscopy of Tissue XIII 2019 - San Francisco, United States
Duration: Feb 4 2019Feb 6 2019

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume10874
ISSN (Print)1605-7422

Conference

ConferenceOptical Tomography and Spectroscopy of Tissue XIII 2019
Country/TerritoryUnited States
CitySan Francisco
Period2/4/192/6/19

Keywords

  • Breast cancer
  • CtTHb reduction
  • Diffuse optical tomography
  • Neoadjuvant chemotherapy
  • Pgr-negative

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Biomaterials
  • Atomic and Molecular Physics, and Optics
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Monitoring total hemoglobin concentration changes across neoadjuvant chemotherapy in PgR-positive and PgR-negative breast cancer with diffuse optical tomography'. Together they form a unique fingerprint.

Cite this